Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
PR Newswire•19/10/2026•08:00 ET
0
Key Highlights
- ➤25% of first qualifying PRV net proceeds allocated to CVR holders
- ➤$50 million aggregate cap applies to CVR holder payments
- ➤October 19 record date attaches one CVR to each outstanding share
- ➤CVRs transfer only with shares unless Atossa’s board detaches them
- ➤No PRV awarded; no product candidate approved or marketing application submitted
Expert Statements
Steven C. Quay, Chairman, President and Chief Executive Officer of Atossa Therapeutics
“Today's record date marks an important step in providing our shareholders with a contractual opportunity to participate in the potential value of Atossa's first qualifying priority review voucher.”
Steven C. Quay, Chairman, President and Chief Executive Officer of Atossa Therapeutics
“Each CVR will be attached to its corresponding share of Atossa common stock and will transfer with that share while stapled.”
Steven C. Quay, Chairman, President and Chief Executive Officer of Atossa Therapeutics
“This structure aligns participation in that potential value with ownership of Atossa common stock, while preserving our flexibility to advance our development programs and allocate capital in the interests of the Company and its shareholders.”
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today PR Newswire
One CVR will attach to each outstanding share of Atossa common stock as of the close of business on October 19, 2026, and shares and CVRs will transfer together while stapled
Get started
Create a free account to read the full story.